Tapan Kadia
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Tapan Kadia
Jul 20, 2024, 14:27 |
Insight
Naveen Pemmaraju: Important paper on AML and Hyperleukocytosis
Naveen Pemmaraju shared a post about a paper titled "Outcomes of Patients With Newly Diagnosed…
Jul 19, 2024, 13:27 |
Insight
Fadi Haddad: Hyperleukocytosis in Acute myeloid leukemia
Fadi Haddad, Assistant Professor at Leukemia Department at MD Anderson Cancer Center, shared a post…
Jul 7, 2024, 10:40 |
Insight
Distinction of AA vs inherited BM failure syndromes
Naveen Pemmaraju shared on X: "Our article just out in Clinical Lymphoma Myeloma Leukemia (CLML)…
Jun 30, 2024, 09:41 |
Insight
MD Anderson Cancer Center’s Research Highlights
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in…
Jun 19, 2024, 23:09 |
Blog
Wei Ying Jen: Very grateful to be standing on the shoulders of giants
Wei Ying Jen, Haematologist and Leukemia Doctor at MD Anderson Cancer Center, shared on X:…
Jun 17, 2024, 07:05 |
Societies
15 Posts You Should Not Miss From EHA 2024!
The European Hematology Association (EHA) Hybrid Congress or EHA2024 will took place in Madrid, Spain…
May 3, 2024, 15:46 |
Blog
Naveen Pemmaraju: When myeloid and lymphoid world experts meet
Naveen Pemmaraju shared a post on X: "When myeloid and lymphoid world experts meet, wonderful…
Dec 24, 2023, 18:42 |
Insight
Naveen Pemmaraju: Important new paper led by Alex Bataller and Tapan Kadia
Naveen Pemmaraju shared on X/Twitter: "Important New paper just out in Blood Advances led by…
Dec 16, 2023, 17:53 |
Drugs
Guillaume Carpentier: Outstanding talk by Tapan Kadia on all oral tx with Dec-C plus Venetoclax in pts with AML ineligible for IC
Guillaume Carpentier, Assistant Professor in the Department of Medicine, Division of Hematology at Queen's University,…
Nov 14, 2023, 01:06 |
Blog
Fadi Haddad: P3 trial of DAC-10 vs 7+3 in older AML pts followed by ASCT
Fadi Haddad, Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas…
Aug 31, 2023, 19:04 |
Insight
Naveen Pemmaraju: Ph2 CLIA with or without sorafenib for upfront AML therapy.
Naveen Pemmaraju, the Executive Director of Cancer Medicine at the MD Anderson Cancer Center, recently…
All:
11
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube